What Does Bristol Myers Squibb (BMY) Zola Cel MS Trial Update Mean?

Bristol Myers Squibb (NYSE:BMY) reported interim Phase 1 Breakfree-2 data on zola-cel CAR T therapy in multiple sclerosis. The readout showed early efficacy signals, including complete B cell depletion and patients remaining off disease modifying therapies. The company also reported a fatal event in the trial, giving investors more detail on zola-cel's emerging risk profile. The Breakfree-2 interim zola-cel data only captures part of the story around Bristol Myers Squibb's broader cell...